[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 53 of about 53
1. Liu JL, Chu PY, Yeh KT, Huang RH: Borderline clear cell adenofibroma with extensive hemorrhagic necrosis. Hematol Oncol Stem Cell Ther; 2010;3(3):158-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline clear cell adenofibroma with extensive hemorrhagic necrosis.
  • Borderline clear cell adenofibroma of the ovary is rather rare since most of clear cell tumors are carcinomas.
  • We report a case of ovarian borderline clear cell adenofibroma in a 52-year-old postmenopausal woman.
  • The tumor had the characteristic histologic features of borderline clear cell adenofibroma except for central extensive hemorrhagic necrosis.
  • The prognosis of borderline clear cell adenofibroma is excellent.
  • [MeSH-major] Adenofibroma / pathology. Hemorrhage / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890073.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


2. Karlberg S, Lipsanen-Nyman M, Lassus H, Kallijärvi J, Lehesjoki AE, Butzow R: Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas. Mod Pathol; 2009 Apr;22(4):570-8
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mulibrey nanism is an autosomal recessive growth disorder caused by mutations in the TRIM37 gene encoding a protein of unknown function.
  • More than half of female patients with Mulibrey nanism develop benign mesenchymal tumors of ovarian sex cord-stromal origin.
  • In addition to tumors of the fibrothecoma group, 18% (4/22) of the patients were observed with epithelial neoplasias, including 2 ovarian adenofibromas, 1 ovarian poorly differentiated adenocarcinoma and 1 endometrial adenocarcinoma.

  • Genetic Alliance. consumer health - Mulibrey Nanism.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329943.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / TRIM37 protein, human
  •  go-up   go-down


3. Gurrera A, Alaggio R, Leone G, Aprile G, Magro G: Biliary adenofibroma of the liver: report of a case and review of the literature. Patholog Res Int; 2010;2010:504584
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary adenofibroma of the liver: report of a case and review of the literature.
  • We herein report the clinicopathologic features of a rare case of biliary adenofibroma (BAF) of the liver in a 79-year-old man.
  • Histological examination was typical of biliary adenofibroma, showing a proliferation of variable-sized tubulocystic structures embedded in a moderately cellular fibrous stroma.
  • Differential diagnosis with Von Meyenburg complex, biliary adenoma, biliary cistadenoma, congenital biliary cystsy, and hepatic benign cystic mesothelioma is provided.
  • The occasionally reported expression of p53 in biliary adenofibroma has suggested that this tumour could represent a premalignant lesion.
  • The absence of both cytological atypia and p53 immunoreactivity in our case confirms that BAF is a benign tumour with an indolent clinical behaviour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151526.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2989712
  •  go-up   go-down


Advertisement
4. Chung YW, Bae HS, Han SI, Song JY, Kim IS, Kang JS: Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report. J Gynecol Oncol; 2010 Dec 30;21(4):269-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma.
  • Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2000 Jan-Feb;55(1):17-20 [10881074.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3487-94 [11032589.001]
  • [Cites] Arch Gynecol Obstet. 2000 Sep;264(2):105-7 [11045336.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):897-902 [11286468.001]
  • [Cites] AJR Am J Roentgenol. 2003 Dec;181(6):1673-5 [14627594.001]
  • [Cites] Breast. 2006 Apr;15(2):142-57 [16289904.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):861-5 [16681774.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(4):561-71 [19062268.001]
  • [Cites] Breast Cancer Res Treat. 1993;25(1):57-63 [8518408.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1749-59 [15550579.001]
  • (PMID = 21278890.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026307
  • [Keywords] NOTNLM ; Breast cancer / Mullerian adenofibroma / Mullerian adenosarcoma / Tamoxifen / Toremifene
  •  go-up   go-down


5. Konishi Y, Sato H, Fujimoto T, Tanaka H, Takahashi O, Tanaka T: Adenofibroma of the endometrium protruding into the vaginal cavity: findings on transvaginal ultrasonography, MRI and CT. J Obstet Gynaecol Res; 2006 Dec;32(6):623-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of the endometrium protruding into the vaginal cavity: findings on transvaginal ultrasonography, MRI and CT.
  • Adenofibroma is a rare benign biphasic neoplasm that is classified into the mixed epithelial and mesenchymal tumor group.
  • We report the case of a 42-year-old woman with adenofibroma of the endometrium protruding into the vagina.
  • Transvaginal ultrasonography revealed the tumor as an intravaginal mass containing multiple cystic components.
  • Although preoperative diagnosis of this rare tumor is very difficult, the combination of MRI, CT, and ultrasonography offers a useful diagnostic tool.
  • [MeSH-major] Adenofibroma / ultrasonography. Endometrial Neoplasms / ultrasonography. Vagina / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100829.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Prat J: Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol; 2005 Feb;18 Suppl 2:S99-111
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous carcinomas of the ovary are rare and can be easily confused with metastatic mucinous carcinomas that may present clinically as a primary ovarian tumor.
  • International Federation of Gynecology and Obstetrics (FIGO) stage is the single most important prognostic factor, and stage I carcinomas have an excellent prognosis; FIGO stage is largely related to the histologic features of the ovarian tumors.
  • However, typical endometrioid glands, squamous differentiation, or an adenofibroma component are each present in 75% of these tumors whereas immunostains for calretinin and alpha-inhibin are negative.
  • Most of these tumors have a favorable outcome and they most likely represent independent primary carcinomas arising as a result of a Mullerian field effect.
  • Transitional cell carcinomas are distinguished from undifferentiated carcinomas by the presence of thick, undulating papillae with smooth luminal borders, microspaces, and tumor cells with distinctive 'urothelial' appearance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492758.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 0 / beta Catenin; 68238-35-7 / Keratins; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 63
  •  go-up   go-down


7. Yamamoto S, Tsuda H, Takano M, Kita T, Kudoh K, Furuya K, Tamai S, Matsubara O: Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Mod Pathol; 2008 Feb;21(2):115-24
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical expression of platelet-derived growth factor receptor-alpha and receptor-beta, platelet-derived growth factor A-chain and B-chain was examined in 31 cases of clear-cell adenocarcinoma and 56 coexisting putative precursor lesions: 17 non-atypical and 19 atypical endometrioses, and 10 non-atypical and 10 atypical clear-cell adenofibroma components.
  • The frequencies of positivity for platelet-derived growth factor receptor-alpha and receptor-beta, and platelet-derived growth factor A-chain increased in accordance with higher cytologic atypia in the putative precursors: 71, 47, and 59% in the 17 non-atypical endometrioses, 84, 73, and 84% in the 19 atypical endometrioses, 0% each in the 10 non-atypical clear-cell adenofibromas, 100, 90, and 90% in the 10 atypical clear-cell adenofibromas, and 97, 97, and 100% in the 31 clear-cell adenocarcinomas, respectively.
  • Positivity for platelet-derived growth factor B-chain increased in accordance with increased atypia in clear-cell adenofibroma: 0% in non-atypical clear-cell adenofibromas, 30% in atypical clear-cell adenofibromas, and 60% in coexisting carcinomas.
  • These results indicate activation of the platelet-derived growth factor pathway in ovarian clear-cell adenocarcinomas and suggest biological differences between carcinomas that arise in association with clear-cell adenofibroma vs endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenofibroma / metabolism. Endometriosis / metabolism. Ovarian Neoplasms / metabolism. Platelet-Derived Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Humans. Immunoenzyme Techniques. Neoplasms, Multiple Primary. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084257.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


8. Chong Y, Eom M, Park KH, Chung HC, Ro JY: Adenofibroma of Skene's Duct: A Case Report. Patholog Res Int; 2010;2010:318973

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of Skene's Duct: A Case Report.
  • Recently, the authors experienced the first case of adenofibroma arising in Skene's glands of a 62-year-old woman with coital pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21152177.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2997287
  •  go-up   go-down


9. Katz L, Levy A, Wiznitzer A, Sheiner E: Pregnancy outcome of patients with dermoid and other benign ovarian cysts. Arch Gynecol Obstet; 2010 May;281(5):811-5
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy outcome of patients with dermoid and other benign ovarian cysts.
  • OBJECTIVE: To investigate pregnancy outcome of patients with dermoid and other benign ovarian cysts.
  • METHODS: A population-based study comparing all pregnancies of women with and without benign ovarian cysts was conducted.
  • A multivariate logistic regression model, with backward elimination, was constructed to find independent risk factors associated with benign ovarian cysts.
  • RESULTS: During the study period there were 212,114 deliveries, of which 93 occurred in patients with benign ovarian cysts.
  • Most of the lesions were benign cyatadenoma (41.9%), 36.7% were dermoid cyst, and 11.8% were adenofibroma, mostly diagnosed during cesarean delivery (76.3%).
  • The mean diameter at diagnosis was 9.05+/-7.6 cm for cystadenoma, 6.09+/-3.0 cm for dermoid cyst and 4.55+/-4.1 cm for adenofibroma.
  • The following conditions were significantly associated with benign ovarian cysts: hypertensive disorder [odds ratio (OR) 3.05; 95% confidence interval (CI) 1.87-4.97], and maternal age (OR 1.04; 95% CI 1.01-1.07).
  • CONCLUSION: The course of pregnancy of patients with dermoid and other benign ovarian cysts, including perinatal outcomes, is favorable.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554342.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


10. Kohashi K, Oda Y, Nakamori M, Yamamoto H, Tamiya S, Toubo T, Kinoshita Y, Tajiri T, Taguchi T, Tsuneyoshi M: Multifocal metanephric adenoma in childhood. Pathol Int; 2009 Jan;59(1):49-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metanephric adenoma is the most commonly occurring member of the metanephric tumor family, which also includes metanephric adenofibroma and metanephric stromal tumor.
  • According to the World Health Organization classification, however, it is not commonly multifocal.
  • Reported herein is the case of a 9-year-old boy with multifocal metanephric adenoma.
  • On immunohistochemistry the tumor cells were positive for vimentin, cytokeratins (CAM5.2, AE1/AE3, and CK18), and WT1, but negative for cytokeratin 7 (CK7) and epithelial membrane antigen (EMA).

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121092.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


11. Paşaoğlu O, Ciftçi E, Tel N, Ozalp S, Acikalin MF: Benign clear cell adenofibroma of the ovary. A case report with literature review. Gynecol Obstet Invest; 2007;64(1):36-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for clear cell adenofibroma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign clear cell adenofibroma of the ovary. A case report with literature review.
  • Most clear cell neoplasms of the ovaries are carcinomas; benign and borderline clear cell tumors are uncommon.
  • To date, only 12 cases of benign clear cell adenofibroma have been reported in the literature.
  • Here we report a case of benign clear cell adenofibroma of the left ovary in a 51-year-old postmenopausal woman.
  • In this article we discussed the criteria for the diagnosis of benign and borderline clear cell adenofibromas and reviewed the literature.
  • [MeSH-major] Adenofibroma / pathology. Adenofibroma / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenofibroma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17202822.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 8
  •  go-up   go-down


12. Hayasaka K, Morita K, Saitoh T, Tanaka Y: Uterine adenofibroma and endometrial stromal sarcoma associated with tamoxifen therapy: MR findings. Comput Med Imaging Graph; 2006 Jul;30(5):315-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenofibroma and endometrial stromal sarcoma associated with tamoxifen therapy: MR findings.
  • Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenofibroma and endometrial stromal sarcoma (ESS).
  • This report describes the MR findings of adenofibroma and ESS associated with tamoxifen therapy.
  • When MRI demonstrates a uterine mass appearing as a heterogeneous mass in the endometrium or myometrium, adenofibroma and ECC must be considered as rare, but possible, diagnoses.
  • [MeSH-major] Adenofibroma / chemically induced. Magnetic Resonance Imaging. Sarcoma, Endometrial Stromal / chemically induced. Tamoxifen / contraindications. Uterine Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890405.001).
  • [ISSN] 0895-6111
  • [Journal-full-title] Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  • [ISO-abbreviation] Comput Med Imaging Graph
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


13. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O: Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways. Virchows Arch; 2009 Nov;455(5):413-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, CCA also occurs in association with clear cell adenofibroma (CCAF).
  • In this study, the expressions of p27(Kip1)-interacting proteins, i.e., p27(Kip1), Skp2, Cks1, cyclin A, cyclin E, and the Ki-67 labeling index (LI), were analyzed in 25 CCAFs (11 benign and 14 borderline) and 15 CCAF-associated CCAs, and compared with the expression status of each protein in the 23 previously studied endometriosis-associated CCAs.
  • Although aberrant expression of all p27(Kip1)-interacting proteins was more frequent in the CCAF-associated CCAs than in the benign CCAFs, statistical significance was found only for Cks1 overexpression.
  • Mean Ki-67 LI increased significantly through benign (4.9%) to borderline (11.1%) CCAF and to CCAF-associated CCA (30.6%), but the latter two values were significantly lower than those in atypical endometriosis (21.4%) and endometriosis-associated CCA (46.9%; P < 0.05, respectively).
  • These data suggest that accumulated alterations of p27(Kip1)-interacting proteins may accelerate the development of CCAs regardless of their carcinogenetic pathways, but that tumor cells in the CCAF-associated pathway appear to show slower cell-cycle progression than those in the endometriosis-associated pathway, possibly accounting for the distinct clinicopathological features of the two CCA subtypes.
  • [MeSH-minor] Adenofibroma / genetics. Adenofibroma / metabolism. Adenofibroma / pathology. Cyclin-Dependent Kinase Inhibitor p27. Endometriosis / genetics. Endometriosis / metabolism. Endometriosis / pathology. Female. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5043-8 [11309491.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1B):675-9 [12680166.001]
  • [Cites] Clin Obstet Gynecol. 1980 Sep;23(3):951-63 [7418292.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):999-1006 [17592265.001]
  • [Cites] Med Electron Microsc. 2003 Mar;36(1):9-17 [12658347.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3534-9 [8758923.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):776-84 [14675314.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Apr 13;282(4):853-60 [11352628.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1707-12 [9563487.001]
  • [Cites] Hepatology. 2000 May;31(5):1068-72 [10796881.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1156-63 [6692303.001]
  • [Cites] Cell. 1995 Sep 22;82(6):915-25 [7553852.001]
  • [Cites] J Pathol. 2008 Sep;216(1):103-10 [18600856.001]
  • [Cites] Mod Pathol. 2007 Apr;20(4):497-507 [17384652.001]
  • [Cites] Histopathology. 2010 May;56(6):740-9 [20546339.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):181-2 [8392791.001]
  • [Cites] Hum Pathol. 1988 Sep;19(9):1080-4 [3417292.001]
  • [Cites] Histopathology. 1997 Mar;30(3):249-55 [9088954.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2922-31 [4052962.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):298-304 [10785482.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jan;15(1):1-9 [8852439.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):487-98 [16428491.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2515-20 [11226270.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1870-8 [10206307.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2776-86 [15838514.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):985-90 [9500460.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):669-77 [10091740.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1756-63 [12738731.001]
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):281-7 [12151151.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):937-42 [18081792.001]
  • [Cites] Reproduction. 2004 Mar;127(3):293-304 [15016949.001]
  • [Cites] Oncol Rep. 2006 Apr;15(4):765-71 [16525656.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):115-24 [18084257.001]
  • (PMID = 19855998.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


14. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor. Arch Gynecol Obstet; 2008 Sep;278(3):283-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor.
  • OBJECTIVE: Adenofibroma is a form of mixed mesodermal tumor in which epithelial and stromal components are benign, and usually arises in the endometrium of postmenopausal women.
  • We report a case of lipoadenofibroma of the endometrium that appeared as an intracavitary mass, which is very unusual because endometrioid adenofibroma rarely contains mature adipose tissue, only the second such case described in detail.
  • CONCLUSION: We suggest that uterine adenofibromas with lipomatous areas belong to the family of mixed tumor of Mullerian origin.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology. Mixed Tumor, Mullerian / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236054.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Tokunaga H, Akahira J, Suzuki T, Moriya T, Sasano H, Ito K, Yaegashi N: Ovarian epithelial carcinoma with estrogen-producing stroma. Pathol Int; 2007 May;57(5):285-90
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her serum estradiol (E2) concentration was 83 pg/mL before treatment, and the endometrial thickness measured by transvaginal ultrasonography was 5 cm, much thicker than that expected for a woman in her 80s.
  • Immunohistochemical studies demonstrated that the enzymes required to produce estrogen were present in the tumor.
  • This case indicates that in addition to stromal tumors, such as granulosa cell tumors, theca cell tumors, adenofibroma and so on, malignant epithelial tumors with a functioning stroma should also be considered when evaluating ovarian tumors with estrogen production in the elderly.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493177.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Estrogens; 4TI98Z838E / Estradiol
  •  go-up   go-down


16. D'Angelo E, Prat J: Uterine sarcomas: a review. Gynecol Oncol; 2010 Jan;116(1):131-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their histopathologic classification was revised by the World Health Organization (WHO) in 2003.
  • A new staging system has been recently designed by the International Federation of Gynecology and Obstetrics (FIGO).
  • RESULTS: Since carcinosarcomas (malignant mixed mesodermal tumors or MMMT) are currently classified as metaplastic carcinomas, leiomyosarcomas remain the most common uterine sarcomas.
  • Adenofibromas may represent well-differentiated adenosarcomas.
  • Immunohistochemical studies of oncoproteins as well as molecular analysis of non-random translocations will undoubtedly lead to an accurate and prognostically relevant classification of these rare tumors.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19853898.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


17. Mondal SK: Adenofibroma and ectopic pregnancy of left fallopian tube: a rare coexistence. J Obstet Gynaecol Res; 2010 Jun;36(3):690-2
Genetic Alliance. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma and ectopic pregnancy of left fallopian tube: a rare coexistence.
  • A rare coexistence of an adenofibroma and ectopic pregnancy in the left fallopian tube is reported.
  • Adenofibroma is a rare benign neoplasm of the fallopian tube, and the fallopian tube is the most common site of ectopic pregnancies.
  • However, coexistence of such rare tumor and ectopic pregnancy is extremely rare.
  • In the present case, the adenofibroma was found at the fimbrial end.
  • [MeSH-major] Adenofibroma / complications. Adenofibroma / pathology. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / pathology. Pregnancy, Tubal / pathology

  • Genetic Alliance. consumer health - Ectopic Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598059.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


18. McCluggage WG, Young RH: Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor. Am J Surg Pathol; 2008 Sep;32(9):1373-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor.
  • The distinction between a primary ovarian mucinous carcinoma or even a borderline mucinous tumor and a metastatic mucinous carcinoma may be difficult.
  • A constellation of clinical, gross pathologic and morphologic features is used in this distinction.
  • One of the most important morphologic features suggesting a metastatic mucinous carcinoma in the ovary is the presence of signet ring cells; these are considered rare in primary ovarian mucinous tumors.
  • In one case, the neoplasm had the architecture of a mucinous adenofibroma but had frankly malignant cells lining glands and forming solid aggregates of cells.
  • A second tumor also had the background of an adenofibroma.
  • Features favoring a primary rather than a metastatic neoplasm are unilateral tumor, low stage, background of adenofibroma or cystadenoma, associated endometriosis in 1 case and an absence of features which are characteristic of secondary mucinous carcinomas in the ovary, such as surface tumor deposits, a nodular growth pattern, and lymphovascular permeation.
  • Immunohistochemistry is of limited value because of overlapping immunophenotype between a primary ovarian mucinous tumor and a metastasis from the stomach, pancreas, biliary tree, appendix, or colorectum, the most likely primary sites for a secondary exhibiting similar features.
  • Our study illustrates that signet ring cells occur rarely in a primary ovarian mucinous tumor; even when conspicuous the features differ from those of the usual Krukenberg tumor.
  • At least some cases of so-called primary Krukenberg tumor may be similar to our cases.
  • However, the designation primary Krukenberg tumor should not be used as, apart from the signet ring cells, a resemblance to a "true" Krukenberg tumor of the secondary type is limited.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Krukenberg Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670351.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Chiarelli S, Buriticá C, Litta P, Ciani S, Guarch R, Nogales FF: An immunohistochemical study of morules in endometrioid lesions of the female genital tract: CD10 is a characteristic marker of morular metaplasia. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4251-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Immunohistochemical analysis of 53 instances of morular metaplasia comprising 1 cyclic endometrium and 52 endometrioid lesions associated with focal glandular complexity corresponding to 9 polyps, 4 atypical polypoid adenomyomas, 24 complex endometrial hyperplasias (18 with and 6 without atypia), 12 grade 1 endometrioid adenocarcinomas in early clinical stages of both uterus and ovary, and three ovarian adenofibromas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857799.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


20. Guinebretière JM, Menet E, Tardivon A, Cherel P, Vanel D: Normal and pathological breast, the histological basis. Eur J Radiol; 2005 Apr;54(1):6-14
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormones are also thought to be the main determinant of the major benign and malignant pathologies encountered in the breast.
  • Benign lesions are more frequent and fibrocystic changes are by far the most common among them.
  • Adenofibroma is the most frequent tumour.
  • [MeSH-major] Breast / pathology. Breast / ultrastructure. Breast Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797289.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 22
  •  go-up   go-down


21. Dinas K, Daniilidis A, Drizis E, Zaraboukas T, Tzafettas J: Incidental diagnosis of atypical polypoid adenomyoma in a young infertile woman. Eur J Gynaecol Oncol; 2009;30(6):701-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical polypoid adenomyoma (APA) is considered to be a rare, benign form of a polypoid mass that exhibits glandular and squamous epithelial cell proliferation with varying degrees of atypia in association with cellular smooth muscle stroma.
  • The differential diagnosis of APA includes complex endometrial hyperplasia with atypia, invasive adenocarcinoma, adenofibroma, adenosarcoma and carcinosarcoma.
  • The recognition of these unusual benign uterine tumors is very important, because they can easily be misdiagnosed.

  • MedlinePlus Health Information. consumer health - Female Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099510.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Wani Y, Notohara K: Ovarian clear cell carcinoma arising in a mucinous cystadenoma. Int J Gynecol Pathol; 2009 Nov;28(6):584-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clear cell components had adenofibroma-like features devoid of significant nuclear atypia or stromal invasion, including distinctive foci of CC with a hobnail appearance and hyperchromatic nuclei surrounded by desmoplastic or hyalinized stroma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851211.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


23. Menegazzo M, Bagatella P, Marson P, Donadel C, De Silvestro G, Corsini A: Reduced mobilisation of hematopoietic stem cells after hepatic resection for malignant liver disease. Pathol Oncol Res; 2008 Dec;14(4):381-5
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced mobilisation of hematopoietic stem cells after hepatic resection for malignant liver disease.
  • Aim of this study has been to determine whether the nature of the hepatic lesion (benign vs. malignant disease) can give rise to a different degree of mobilisation of HSCs.
  • Two groups of patients were selected: the first included seven patients undergoing hepatic resection (five major and two minor) for a benign liver disease (focal nodular hyperplasia, hemangioma cavernosa, angioma, biliary adenofibroma) and the second included seven patients undergoing hepatic resection (five major and two minor) for a malignant (either primary or secondary) liver disease.
  • In the group undergoing hepatic resection for a benign liver disease, a significant increase of CD34+ cells, both in percentage (0.082 +/- 0.043 vs. 0.048 +/- 0,026, p = 0.041) and in absolute number (8.14 +/- 5.95 vs. 3.26 +/- 2.63, p = 0.018) have been documented, as opposed to the group of patients affected with a malignant liver disease, where no significant variation has been observed (CD34+ %: 0.044 +/- 0.033 vs. 0.041 +/- 0.031, p: n.s.
  • ) These results show a different bone marrow response to the surgical liver resection depending on the nature of the lesion, thus emphasizing a reduced mobilisation of HSCs in the malignant diseases.
  • [MeSH-major] Cell Movement / physiology. Hematopoietic Stem Cells / cytology. Hepatectomy. Liver Diseases / surgery. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752047.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


24. McCluggage WG: My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol; 2006 Aug;59(8):801-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topics such as endometritis, endometrial polyps, changes that are induced by hormones and tamoxifen within the endometrium, endometrial metaplasias and hyperplasias, atypical polypoid adenomyoma, adenofibroma, adenosarcoma, histological types of endometrial carcinoma and grading of endometrial carcinomas are discussed with regard to endometrial biopsy specimens rather than hysterectomy specimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Jun;54(6):435-40 [11376015.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):877-9 [11557783.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1347-54 [11684950.001]
  • [Cites] Am J Obstet Gynecol. 2002 Apr;186(4):651-7 [11967486.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):145-84 [11981113.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):326-31 [11986334.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jul;13(3):248-58 [7928058.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):164-8 [7959278.001]
  • [Cites] J Clin Pathol. 1994 Sep;47(9):827-33 [7962652.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):81-6 [7804981.001]
  • [Cites] Am J Surg Pathol. 1995 Apr;19(4):417-32 [7694943.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):645-51 [7752269.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jul;18(3):220-5 [12090590.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):383-90 [12352187.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 [12445244.001]
  • [Cites] J Clin Pathol. 2003 Apr;56(4):305-7 [12663645.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):395-8 [12692205.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):191-7 [8600069.001]
  • [Cites] Gynecol Oncol. 1996 May;61(2):167-74 [8626128.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jul;15(3):222-9 [8811383.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):33-7 [8986530.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1997 Apr;72(2):175-80 [9134398.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Jun;104(6):748-50 [9197885.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):434-40 [9277658.001]
  • [Cites] Hum Pathol. 1998 Jun;29(6):551-8 [9635673.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):1012-9 [9706982.001]
  • [Cites] Int J Gynecol Pathol. 1998 Oct;17(4):302-11 [9785130.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):130-7 [10202670.001]
  • [Cites] Histopathology. 1999 Jul;35(1):44-9 [10383713.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1102-8 [10478671.001]
  • [Cites] Histopathology. 2004 Dec;45(6):625-32 [15569054.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):1-6 [15623473.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):75-82 [15389257.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):324-30 [15529181.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):295-304 [15725797.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):417-9 [15790709.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):939-43 [14562291.001]
  • [Cites] Adv Anat Pathol. 2003 Nov;10(6):301-18 [14581820.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):129-37 [15084841.001]
  • [Cites] Adv Anat Pathol. 2004 May;11(3):162-71 [15096730.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1057-62 [15252313.001]
  • [Cites] Arch Pathol Lab Med. 2004 Sep;128(9):1000-3 [15335255.001]
  • [Cites] Am J Surg Pathol. 1980 Dec;4(6):525-42 [7212146.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):354-66 [6263458.001]
  • [Cites] Am J Surg Pathol. 1981 Jul;5(5):473-82 [7282995.001]
  • [Cites] Cancer. 1982 Jun 15;49(12):2547-59 [7074572.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):719-20 [6476198.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] J Clin Pathol. 1985 Jun;38(6):644-52 [3891790.001]
  • [Cites] Am J Clin Pathol. 1986 Aug;86(2):139-45 [3739968.001]
  • [Cites] Am J Pathol. 1987 Apr;127(1):66-73 [3565538.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):225-35 [3182169.001]
  • [Cites] Lancet. 1989 Feb 18;1(8634):375 [2563519.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):125-31 [2714930.001]
  • [Cites] Am J Clin Pathol. 1989 Jun;91(6):664-72 [2543209.001]
  • [Cites] Mod Pathol. 1990 Mar;3(2):120-8 [2326248.001]
  • [Cites] Am J Obstet Gynecol. 1992 Sep;167(3):667-74 [1530020.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):485-90 [8383191.001]
  • [Cites] Am J Clin Pathol. 1993 Jun;99(6):741-5 [8322711.001]
  • [Cites] Int J Gynecol Pathol. 1999 Oct;18(4):293-6 [10542935.001]
  • [Cites] Int J Gynecol Pathol. 1999 Oct;18(4):304-9 [10542937.001]
  • [Cites] Mod Pathol. 1999 Dec;12(12):1137-42 [10619266.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):814-24 [10679651.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] J Pathol. 2000 Mar;190(4):462-9 [10699996.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):797-806 [10843281.001]
  • [Cites] BJOG. 2000 Oct;107(10):1312-4 [11028588.001]
  • (PMID = 16873562.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  • [Other-IDs] NLM/ PMC1860448
  •  go-up   go-down


25. Yamamoto S, Tsuda H, Takano M, Hase K, Tamai S, Matsubara O: Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway. J Pathol; 2008 Sep;216(1):103-10
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway.
  • Although the clear-cell adenofibroma (CCAF), a major form of benign and borderline ovarian clear-cell tumour, has been suggested as another precursor for clear-cell adenocarcinoma (CCA), there is no supportive genetic evidence for this presumption.
  • To examine the genetic linkage between CCAF and CCA of the ovary, we conducted allelotype analysis for both CCAF and adjacent CCA components in 14 cases of CCA associated with benign CCAF and/or borderline CCAF.
  • For all informative loci, the frequency of LOH in adenocarcinoma was 49% (54/110 loci), and was significantly higher than those in the components of benign CCAF (22%, 20/92 loci) and borderline CCAF (30%, 25/83 loci) (chi(2) test; p<0.05, respectively).
  • The concordance rate in allelic patterns at all informative loci was 74% between benign CCAF and adenocarcinoma components, 81% between borderline CCAF and adenocarcinoma components, and 95% between benign CCAF and borderline CCAF components.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenofibroma / genetics. Biomarkers, Tumor / analysis. Ovarian Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18600856.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Bossuyt V, Medeiros F, Drapkin R, Folkins AK, Crum CP, Nucci MR: Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma. Int J Gynecol Pathol; 2008 Jul;27(3):390-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma.
  • Fallopian tube adenofibromas (FTAs) are considered rare, but their frequency has never been determined by systematic sampling of this organ.
  • To determine the morphological spectrum and prevalence of FTAs, we analyzed a consecutive series of fallopian tubes removed during surgery for a wide range of disorders.
  • Fallopian tube adenofibromas less than 3 mm were classified as incipient adenofibromas (iFTAs).
  • The association of FTAs with ovarian adenofibromas (OAs) was also evaluated.
  • Twenty-six of 28 (30% overall frequency) consecutively examined bilateral fallopian tube specimens contained adenofibromas (FTAs and iFTAs); all confined to the fimbria.
  • Whether the shared tumor phenotype in these 2 organs is coincidental or interdependent bears further investigation.
  • [MeSH-major] Adenofibroma / pathology. Fallopian Tube Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580316.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Bettaieb I, Mekni A, Bellil K, Haouet S, Bellil S, Kchir N, Chelly H, Zitouna M: Endometrial adenofibroma: a rare entity. Arch Gynecol Obstet; 2007 Mar;275(3):191-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenofibroma: a rare entity.
  • Endometrial adenofibroma is an uncommon mullerian mixed tumor composed of benign epithelial and mesenchymal components.
  • This tumor must be distinguished from other malignant lesions of the uterus, particularly adenosarcoma.
  • The authors report three cases of endometrial adenofibroma and discuss their clinical and histopathologic features.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858575.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. McCluggage WG: Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol; 2010 Mar;17(2):122-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcoma is an uncommon, but not rare, mixed tumor containing a neoplastic but benign or mildly atypical epithelial element and a sarcomatous, usually low-grade, stromal component.
  • Characteristic histologic features include a low power "phyllodes-like" architecture with leaf-like projections lined by a variety of benign Mullerian type epithelia, sometimes with squamous metaplasia.
  • The stroma may be uniformly cellular but there is typically increased cellularity around the epithelial elements, resulting in the formation of a cambium layer.
  • Using the World Health Organization definition, stromal mitotic activity of 2 or more per 10 high-power fields is required for a diagnosis of adenosarcoma but in practice the diagnosis is made with stromal mitotic activity less than this if the characteristic architecture and cambium layer is present.
  • Adenosarcoma may be confused with a variety of lesions and one of the main differential diagnoses is adenofibroma in which the stromal component is, by definition, morphologically benign.
  • However, occasional adenofibromas recur or even metastasize.
  • As such, it has been suggested that all adenofibromas should be classified as adenosarcomas, albeit with low-malignant potential.
  • [MeSH-minor] Adenofibroma / pathology. Aged. Aged, 80 and over. Female. Humans. Ovarian Neoplasms / pathology. Postmenopause. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179434.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


29. Sciallis AP, Aubry MC, Bell DA: Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case. Int J Gynecol Pathol; 2009 Sep;28(5):447-52
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case.
  • In one of the masses, the neoplastic cells seemed to arise from a serous adenofibroma.
  • The tumor was confined to the ovaries without evidence of metastatic spread.
  • Although morphologically resembling an endometrioid-type neoplasm, immunohistochemical and molecular studies were more consistent with a serous phenotype, especially in light of its apparent origination from a serous adenofibroma.
  • We agree with previous observations suggesting that although the neoplasm seems morphologically worrisome, it may actually portend a more benign clinical course.
  • [MeSH-minor] Adenofibroma / pathology. Aged. Aortic Aneurysm, Thoracic / complications. Aortic Aneurysm, Thoracic / pathology. Aortic Rupture / complications. Aortic Rupture / pathology. Autopsy. Cell Differentiation. Female. Humans. Immunohistochemistry. Incidental Findings

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696614.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Yemelyanova A, Mao TL, Nakayama N, Shih IeM, Kurman RJ: Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion. Am J Surg Pathol; 2008 Dec;32(12):1800-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In rare cases, the entire tumor is composed of macropapillae.
  • In these cases, the question of whether this is an invasive carcinoma or an unusual type of adenofibroma has been raised.
  • In addition to a detailed morphologic analysis, the mutational status of KRAS and BRAF in the macropapillary, noninvasive, and invasive MPSC components was analyzed by nucleotide sequencing.
  • There were 14 cases containing macropapillae (11 cases of LGSC, 2 cases of atypical proliferative serous tumor (APST) with microinvasion, and 1 case of APST with a focus of LGSC with macropapillae in perivaginal soft tissue).
  • Molecular analysis of the primary tumor components (macropapillary, noninvasive, and invasive MPSC and/or APST) was performed in 7 cases and of a lymph node metastasis with macropapillae in 1 case.
  • In one of these cases, macropapillae in the lymph node metastasis contained a KRAS mutation identical to the primary tumor.
  • The BRAF mutation identified in 1 case was identical in all components of the ovarian tumor.
  • The identical mutations in the macropapillae and the other tumor components in each case indicate that they are clonally related.
  • The finding of macropapillae within lymph nodes supports the interpretation that the macropapillary component is another manifestation of invasion in LGSC.
  • The recognition of this pattern is important, especially in cases when a tumor is composed entirely of macropapillae.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):1-7 [16462151.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):419-32 [11257616.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Pathol. 2004 Jun;203(2):617-9 [15141374.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):934-48 [15297961.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] J Pathol. 2006 Dec;210(4):405-11 [17096315.001]
  • (PMID = 18779727.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116184-01A2; United States / NCI NIH HHS / CA / R01 CA116184; United States / NCI NIH HHS / CA / R01 CA116184-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS77789; NLM/ PMC2706134
  •  go-up   go-down


31. Chen XD, Shi HY, Zhang XF: [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus]. Zhonghua Fu Chan Ke Za Zhi; 2007 Apr;42(4):219-21
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus].
  • OBJECTIVE: To study the clinical and pathologic features, histological criteria and pathologic factors contributing to diagnosis of mixed epithelial and mesenchymal tumors (mixed müllerian tumors, MMT) of the uterus.
  • METHODS: A retrospective study of 102 cases of MMT of the uterus (74 adenofibromas including 9 recurrent cases, 3 atypical polypoid adenomyomas, 2 carcinofibromas, 10 adenosarcomas and 13 carcinosarcomas) was undertaken.
  • Benign MMT usually presented as exophytic polypoid masses extending into the uterine cavity or protruding through the external os, often broad-based, lobulated and papillary.
  • It was hard to distinguish low-grade malignant MMT from the benign ones by gross appearance.
  • MMT were classified according to whether these elements were benign or malignant.
  • Nine cases of adenofibroma without unique features for the diagnosis of adenosarcoma recurred at postoperative intervals of 3 to 96 months.
  • The recurrent adenofibromas may be a kind of borderline tumors with benign appearances and malignant behavior.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / pathology. Adenomyoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Epithelium / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631758.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. McCluggage WG, Young RH: Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors). Am J Surg Pathol; 2007 Apr;31(4):592-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The converse situation, mimicry of an endometrioid neoplasm by a sex cord-stromal tumor, has not been emphasized.
  • The proportion of the tumor made up of pseudoendometrioid tubules ranged from 10% to >90%.
  • When widespread, their presence sometimes resulted in consideration of a borderline endometrioid adenofibroma or a well-differentiated endometrioid adenocarcinoma.
  • The presence of more typical Sertoli cell elements and Leydig cells, an absence of squamous elements, endometriosis or associated adenofibroma, and the characteristic immunophenotype assist in diagnosis.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414107.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Yamamoto S, Tsuda H, Suzuki K, Takano M, Tamai S, Matsubara O: An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway. Virchows Arch; 2009 Sep;455(3):261-70
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.
  • Patterns of allele loss (loss of heterozygosity (LOH)) were studied to identify the genetic backgrounds underlying the two putative carcinogenic pathways of ovarian clear-cell adenocarcinoma: carcinomas thought to arise in endometriosis (endometriosis-associated carcinomas, 20 cases) and carcinomas thought to be derived from clear-cell adenofibroma ((CCAF)-associated carcinomas, 14 cases).
  • Each tumor was assessed for LOH at 24 polymorphic loci located on 12 chromosomal arms: 1p, 3p, 5q, 8p, 9p, 10q, 11q, 13q, 17p, 17q, 19p, and 22q.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Adenocarcinoma, Clear Cell / genetics. Adenofibroma / complications. Endometriosis / complications. Loss of Heterozygosity. Ovarian Neoplasms / genetics
  • [MeSH-minor] Alleles. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / analysis. Immunohistochemistry. Von Hippel-Lindau Tumor Suppressor Protein / analysis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 May 19;88(10):1578-83 [12771925.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4456-60 [8402612.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2393-8 [8485726.001]
  • [Cites] Clin Obstet Gynecol. 1980 Sep;23(3):951-63 [7418292.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):999-1006 [17592265.001]
  • [Cites] Med Electron Microsc. 2003 Mar;36(1):9-17 [12658347.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3534-9 [8758923.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):776-84 [14675314.001]
  • [Cites] Science. 1995 Jun 23;268(5218):1749-53 [7792600.001]
  • [Cites] Oncology. 2000 Jun;59(1):50-6 [10895067.001]
  • [Cites] Hum Mutat. 1994;3(3):283-91 [8019564.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1707-12 [9563487.001]
  • [Cites] Oncogene. 1998 Nov 5;17(18):2359-65 [9811467.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):844-53 [19342944.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1156-63 [6692303.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):311-7 [17532031.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):429-38 [8123469.001]
  • [Cites] J Pathol. 2008 Sep;216(1):103-10 [18600856.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):111-6 [18097583.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Cancer Res. 1991 Aug 1;51(15):4045-51 [1677312.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1310-20 [17555795.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):181-2 [8392791.001]
  • [Cites] Hum Pathol. 1988 Sep;19(9):1080-4 [3417292.001]
  • [Cites] Histopathology. 1997 Mar;30(3):249-55 [9088954.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2922-31 [4052962.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):298-304 [10785482.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jan;15(1):1-9 [8852439.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jun;36(6):337-43 [16818478.001]
  • [Cites] Diagn Cytopathol. 2001 May;24(5):328-32 [11335962.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5118-22 [1655245.001]
  • [Cites] Reproduction. 2004 Mar;127(3):293-304 [15016949.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):115-24 [18084257.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):950-4 [8640783.001]
  • [Cites] Jpn J Cancer Res. 2002 Jul;93(7):798-806 [12149146.001]
  • (PMID = 19655165.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 2.3.2.27 / Von Hippel-Lindau Tumor Suppressor Protein; EC 6.3.2.- / VHL protein, human
  •  go-up   go-down


34. Haberal A, Cil AP, Gunes M, Cavusoglu D: Papillary adenofibroma of the cervix: a case report. Ultrasound Obstet Gynecol; 2005 Aug;26(2):186-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenofibroma of the cervix: a case report.
  • Adenofibroma is an extremely rare benign biphasic neoplasm that is classified into the mixed epithelial and mesenchymal tumor group.
  • Preoperative diagnosis of this tumor is usually difficult.
  • We describe the case of a 55-year-old woman with papillary cervical adenofibroma, which appeared as a cervical mass containing multiple cystic components on transvaginal ultrasound.
  • This lesion appears to be clinically and histologically benign but must be differentiated from malignant lesions of the uterus, particularly from adenosarcoma, which can be suggestive of adenofibroma.
  • Accurate diagnosis of these benign tumors permits appropriate counseling of patients.
  • [MeSH-major] Adenofibroma / ultrasonography. Uterine Cervical Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 16041681.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Yang JX, Han YJ, Zheng H, Luo RC: [Expression of PAK4 in breast cancer and benign breast pathological changes]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):981-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PAK4 in breast cancer and benign breast pathological changes].
  • METHOD: PAK4 expression was detected in 35 cases of normal breast, 22 breast cystic hyperplasia, 28 breast adenofibroma, 37 breast cancer (including 7 non-invasive cancer, 9 early invasive cancer and 21 invasive cancer) and 13 metastatic breast cancer tissues using immunohistochemistry for a comparison of PAK4 expression and distribution.
  • PAK4 positivity rates increased in the order of normal breast tissues, benign changes (including breast cystic hyperplasea and breast adenoma), breast cancer and metastatic cancer tissues; in the cancer tissues, the positivity rates increased in the order of non-invasive breast tumor, early invasive tumor and invasive tumor tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. p21-Activated Kinases / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501374.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.11 / PAK4 protein, human; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


36. Tahlan A, Nanda A, Mohan H: Uterine adenomyoma: a clinicopathologic review of 26 cases and a review of the literature. Int J Gynecol Pathol; 2006 Oct;25(4):361-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomyoma of the uterus is a circumscribed nodular aggregate of benign endometrial glands surrounded by endometrial stroma with leiomyomatous smooth muscle bordering the endometrial stromal component.
  • The criterion used for case identification was a circumscribed mass composed of benign endometrial glands with a stromal component consisting of endometrial type stroma surrounded by leiomyomatous smooth muscle.
  • Thirteen patients underwent panhysterectomy; 7, total hysterectomy; 1, subtotal hysterectomy; 4, polypectomy or tumor removal; and 1, curettage.
  • The glands were lined by benign proliferative pseudostratified columnar epithelium.
  • Adenomyomas have to be distinguished from a number of other lesions, for example, adenomyosis, leiomyoma with entrapped glands, atypical polypoid adenomyoma, endometrial polyps, adenofibroma, and adenosarcoma.
  • This study highlights the importance of correctly identifying this fairly common entity and helps to distinguish adenomyoma from other similar appearing benign and malignant lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990713.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


37. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Microscopically, they may be difficult to distinguish from adenofibromas.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Six developed metastases and 5 of them died of tumor.
  • Both were initially underdiagnosed as adenofibromas.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • These findings suggest that some of the tumors currently classified as adenofibromas, on the basis of their low mitotic count and lack of significant nuclear atypia, are, in fact, well-differentiated adenosarcomas.
  • [MeSH-major] Adenofibroma / pathology. Adenosarcoma / pathology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


38. Vang R, Shih IeM, Kurman RJ: Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol; 2009 Sep;16(5):267-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They evolve from adenofibromas or borderline tumors, have frequent mutations of the KRAS, BRAF, or ERBB2 genes, and lack TP53 mutations (Type I pathway).
  • Identification of a precursor lesion in the ovary has been elusive and therefore the origin of ovarian carcinoma has been described as de novo.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1994-2000 [15753399.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):707-23 [15897738.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1034-41 [16006797.001]
  • [Cites] Int J Gynecol Pathol. 2005 Oct;24(4):363-8 [16175083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 [16172393.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1482-9 [16224215.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1049-54 [16226103.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2807-16 [16284991.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:123-8 [16515579.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):484-9 [16681715.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):361-8 [16880307.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1209-21 [17001150.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5944-50 [17062665.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):703-8 [16828848.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18739-44 [17130457.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):653-63 [17460447.001]
  • [Cites] Histopathology. 2007 May;50(6):773-9 [17493241.001]
  • [Cites] Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6 [17504374.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):625-9 [17320156.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1007-12 [17592266.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):398-403 [17997146.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):510-4 [18155273.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [17692090.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Histopathology. 2008 Aug;53(2):127-38 [18298580.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1566-71 [18724243.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):519-23 [18928667.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1667-74 [18769340.001]
  • [Cites] Am J Surg Pathol. 2008 Dec;32(12):1800-6 [18779727.001]
  • [Cites] Br J Cancer. 2008 Dec 16;99(12):2020-8 [19018267.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4036-42 [19383911.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1220-4 [19461510.001]
  • [Cites] Am J Surg Pathol. 2009 Jul;33(7):1037-41 [19238079.001]
  • [Cites] Am J Surg Pathol. 2009 Oct;33(10):1504-14 [19623034.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] J Surg Oncol. 2000 Mar;73(3):148-52 [10738268.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91 [10880552.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2076-84 [11066048.001]
  • [Cites] Am J Hum Genet. 2001 Mar;68(3):700-10 [11179017.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):201-6 [11161860.001]
  • [Cites] Int J Gynecol Pathol. 2001 Oct;20(4):323-8 [11603214.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):61-7 [11773283.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):47-59 [11823973.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1396-406 [12237285.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):148-54 [12694669.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):447-52 [12798710.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):162-9 [15084845.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Obstet Gynecol. 2004 Apr;190(4):1039-45 [15118638.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):265-72 [15213603.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):918-33 [15297960.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):934-48 [15297961.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6432-6 [15475429.001]
  • [Cites] Eur J Surg Oncol. 2004 Nov;30(9):976-81 [15498644.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):121-9 [644422.001]
  • [Cites] Gynecol Oncol. 1993 Sep;50(3):347-51 [8406199.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):393-6 [8774644.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):663-7 [9237175.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Virchows Arch. 1999 Feb;434(2):117-20 [10071245.001]
  • [Cites] Am J Obstet Gynecol. 1950 Jan;59(1):58-67, illust [15399626.001]
  • (PMID = 19700937.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129080-02; United States / NCI NIH HHS / CA / R01 CA129080-02; United States / NCI NIH HHS / CA / R01CA116184; United States / NCI NIH HHS / CA / R01 CA116184; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / R01CA129080; United States / NCI NIH HHS / CA / R01 CA103937; United States / NCI NIH HHS / CA / R01CA103937
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / ERBB2IP protein, human; 0 / KRAS protein, human; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 87
  • [Other-IDs] NLM/ NIHMS139803; NLM/ PMC2745605
  •  go-up   go-down


39. Vujanić GM: [Renal tumours of childhood: the last 100 years and where to from here]. Srp Arh Celok Lek; 2008 May;136 Suppl 2:142-51
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By studying a large series of renal tumours of childhood collected through international multicentre trials, their clinico-pathological features have been better recognised resulting in more appropriate treatment and better prognosis, numerous new tumour entities have been identified, and thank to new molecular biology studies and techniques, many tumour genes and genetic abnormalities which are important in tumorigenesis have been found.
  • Finally, some new, kidney-specific entities have been recognised too (metanephric stromal tumour, metanephric adenofibroma, anaplastic sarcoma of the kidney).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18924485.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia
  • [Number-of-references] 56
  •  go-up   go-down


40. Eren F, Akpulat S, Gokaslan H: Primary leiomyoma of the ovary co-existing with serous cystadenofibroma. APMIS; 2005 Feb;113(2):145-7
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On cut section the tumor had a solid and a cystic component.
  • Sections taken from the solid component revealed a tumor composed of interlacing bundles of fusiform cells, resembling a leiomyoma.
  • Sections taken from the nodule in the cystic part revealed an adenofibroma.
  • As far as we know, this is the first case of a co-existing leiomyoma and serous cystadenofibroma in the ovary, and we think it will broaden the histological spectrum of primary ovarian leiomyomas.
  • [MeSH-major] Adenofibroma / pathology. Leiomyoma / pathology. Neoplasms, Multiple Primary / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723690.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins
  •  go-up   go-down


41. Sokalska A, Timmerman D, Testa AC, Van Holsbeke C, Lissoni AA, Leone FP, Jurkovic D, Valentin L: Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses. Ultrasound Obstet Gynecol; 2009 Oct;34(4):462-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Within the framework of a European multicenter study, the International Ovarian Tumor Analysis study, comprising nine ultrasound centers, women with at least one adnexal mass were examined with gray-scale and color Doppler ultrasonography by experienced ultrasound examiners.
  • Using pattern recognition the examiners classified each mass as benign or malignant and suggested a specific diagnosis (e.g. dermoid cyst or endometrioma).
  • RESULTS: A total of 1066 women were included, of whom 800 had a benign mass and 266 a malignant mass.
  • The sensitivity was highest for benign teratoma/dermoid cysts (86%, 100/116), hydrosalpinges (86%, 18/21), peritoneal pseudocysts (80%, 4/5) and endometriomas (77%, 153/199), and lowest for functional cysts (17%, 4/24), paraovarian/parasalpingeal cysts (14%, 3/21), benign rare tumors (11%, 1/9), adenofibromas (8%, 3/39), simple cysts (6%, 1/18) and struma ovarii (0%, 0/5).
  • Dermoid cysts, hydrosalpinges, functional cysts, paraovarian cysts, peritoneal pseudocysts, fibromas/fibrothecomas and simple cysts were never misdiagnosed as malignancies by the ultrasound examiner, whereas more than 10% of inflammatory processes, adenofibromas and rare benign tumors including struma ovarii were misdiagnosed as malignancies.
  • CONCLUSIONS: Using subjective evaluation of gray-scale and Doppler ultrasound findings it is possible to make an almost conclusive diagnosis of a dermoid cyst, endometrioma and hydrosalpinx.
  • [MeSH-major] Adnexal Diseases / ultrasonography. Clinical Competence / standards. Pattern Recognition, Automated
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Ovarian Neoplasms / classification. Ovarian Neoplasms / ultrasonography. Predictive Value of Tests. Prognosis. Risk Factors. Sensitivity and Specificity. Ultrasonography, Doppler

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19685552.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


42. Ben Hassouna J, Damak T, Ben Slama A, Chargui R, Ben Dhiab T, Khomsi F, Gamoud A, Boussen H, Rahal K: Breast carcinoma arising within fibroadenomas. Report of four observations. Tunis Med; 2007 Oct;85(10):891-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibroadenoma is a frequent benign breast tumor affecting young woman.
  • The incidence of a carcinoma within adenofibromas is estimated at 0.1 to 0.3%.
  • AIM: The purpose of this study was to evaluate the outcome of patients with breast carcinoma arising within adenofibroma and to determine the clinical characteristics and the prognosis of this rare entity.
  • The treatment consisted of a conservative treatment in two cases and a mastectomy plus axillary node dissection in the two others.
  • CONCLUSION: Every benign mammary nodule must necessarily be verified surgically to avoid misdiagnosing any carcinomatous area because at this stage its prognosis is better.
  • [MeSH-major] Adenofibroma / pathology. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Breast Cyst / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy. Metaplasia. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236815.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


43. Cheuk W, Chan JK: Advances in salivary gland pathology. Histopathology; 2007 Jul;51(1):1-20
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Newly recognized entities include: sclerosing polycystic adenosis (with recent molecular evidence supporting its neoplastic nature), sclerosing mucoepidermoid carcinoma with eosinophilia, keratocystoma, adenoma with additional stromal component (lymphadenoma, lipoadenoma and adenofibroma), cribriform adenocarcinoma of the tongue and signet ring adenocarcinoma of minor salivary gland.
  • Known tumour entities with new findings include: salivary duct carcinoma (with newly recognized mucinous, micropapillary and sarcomatoid variants), intraductal carcinoma (with controversies in terminology), mucoepidermoid carcinoma (with newly proposed grading parameters and oncocytic variant), epithelial-myoepithelial carcinoma (with newly recognized morphological variants), small cell carcinoma (with most cases being related to Merkel cell carcinoma), extranodal marginal zone B-cell lymphoma (with specific chromosomal translocation) and chronic sclerosing sialadenitis (being a component of IgG4-related sclerosing disease).
  • Progression of salivary gland tumours can take the form of malignant transformation of a benign tumour, progression from low-grade to high-grade carcinoma, dedifferentiation, or stromal invasion of an in situ carcinoma.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Disease Progression. Gene Expression Regulation, Neoplastic. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17539914.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 142
  •  go-up   go-down


44. Gatt N, Attard J, Degaetano J: Adenofibroma of the testis. J Clin Pathol; 2009 Jun;62(6):558-60
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of the testis.
  • Adenofibromas of the testicular parenchyma are exceptional with only one case published in the literature.
  • Whereas adenofibromas of mullerian derivatives are well described, testicular tumours resembling surface ovarian epithelium are rare.
  • We describe a case of adenofibroma discovered incidentally while investigating for a hydrocoele in a 57-year-old patient.
  • Histological and immunohistochemical evaluation confirmed the lesion as being a serous adenofibroma with immunohistochemical properties analogous to its ovarian counterpart.
  • [MeSH-major] Adenofibroma / pathology. Testicular Hydrocele / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474357.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Keratin-7; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


45. Shatova OP, Borzenko BG, Zinkovich II, Sedakov IE: [Lactate dehydrogenase, adenosine deaminase and thymidine phosphorylase activity of blood and tissues in breast cancer]. Ukr Biokhim Zh (1999); 2009 Jul-Aug;81(4):88-93
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lactate dehydrogenase (LDH), adenosine deaminase and thymidine phosphorylase activity was analyzed in the blood serum, primary tumor and adjacent uninvolved breast tissues from 49 women with adenocarcinoma and from 10 ones with benign adenofibroma.
  • Serum LDH level reflects cell membrane alterations not only in the tumor node cells but also to a greater extent--in the surrounding unmalignant tissues.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387638.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.4.2.4 / TYMP protein, human; EC 2.4.2.4 / Thymidine Phosphorylase; EC 3.5.4.4 / ADA protein, human; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


46. Piotrowski Z, Canter DJ, Kutikov A, Al-Saleem T, Pei J, Testa JR, Uzzo RG: Metanephric adenofibroma: robotic partial nephrectomy of a large Wilms' tumor variant. Can J Urol; 2010 Aug;17(4):5309-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric adenofibroma: robotic partial nephrectomy of a large Wilms' tumor variant.
  • PURPOSE: A case of the rare, benign, Wilms' tumor (WT) variant, metanephric adenofibroma (MAF), is presented.
  • Pathologic diagnosis at our institution was confirmed as a MAF by the National Wilms' Tumor Study Group (NWTSG).
  • [MeSH-major] Adenofibroma / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods. Robotics. Wilms Tumor / surgery

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20735912.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


47. Boruban MC, Jaishuen A, Sirisabya N, Li Y, Zheng HG, Deavers MT, Kavanagh JJ: Ovarian endometriosis associated with carcinoma and sarcoma: case report. Eur J Gynaecol Oncol; 2008;29(4):393-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometriosis is a common clinical disorder that shares certain characteristics, metastasis and recurrence, with malignant neoplasms.
  • Here, we report the case of a 32-year-old woman who presented with infertility and a pelvic mass.
  • The pathologic findings revealed bilateral endometrioid adenofibroma of low malignant potential, which was associated with endometrioid intraepithelial carcinoma in the left ovary and high-grade sarcoma in the right ovary.
  • The optimal treatment for endometriosis-associated ovarian cancer depends on the type of malignancy; simultaneously occurring multiple tumor types should be treated individually.
  • [MeSH-major] Carcinoma / etiology. Endometriosis / complications. Ovarian Diseases / complications. Ovarian Neoplasms / etiology. Sarcoma / etiology


48. Pelosi G, Rodriguez J, Viale G, Rosai J: Salivary gland-type tumors with myoepithelial differentiation arising in pulmonary hamartoma: report of 2 cases of a hitherto unrecognized association. Am J Surg Pathol; 2006 Mar;30(3):375-87
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors with myoepithelial differentiation arising in pulmonary hamartoma: report of 2 cases of a hitherto unrecognized association.
  • Reported is a hitherto unrecognized association of pulmonary hamartomas with salivary gland-type tumors showing myoepithelial differentiation, namely, a case of myoepithelioma arising in a otherwise classic hamartoma with cartilage predominance, and a case of malignant mixed tumor arising in a predominantly fibrous hamartoma resembling müllerian adenofibroma.
  • The myoepithelioma patient was well with no signs of recurrent disease at 6-month clinical control, but she was then lost to follow-up; the malignant mixed tumor patient is alive and well after 6 months since operation.
  • Both tumors presented with morphologic and immunohistochemical features of myoepithelial cells, and we interpret them as being derived from a myoepithelial-like stromal cell population found within the hamartomatous areas, which is also consistently detected in classic pulmonary hamartoma.
  • The lack of individual cell necrosis, mitotic activity, cell atypia, and pulmonary parenchyma infiltration supported a diagnosis of benign or unproven malignant potential tumor for the myoepithelioma, whereas the reverse held true for the other tumor in which the diagnosis of malignant mixed tumor of the lung was rendered.
  • [MeSH-major] Hamartoma / pathology. Lung Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor. Biopsy, Needle. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lung Diseases / metabolism. Lung Diseases / pathology. Lung Diseases / surgery. Salivary Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538059.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


49. Scurry J, van der Putte SC, Pyman J, Chetty N, Szabo R: Mammary-like gland adenoma of the vulva: review of 46 cases. Pathology; 2009;41(4):372-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unusual vulvar tumours, which have been previously reported as erosive adenomatosis, sclerosing adenosis, papillary adenofibroma, syringocystadenoma papilliferans, etc., are variants of MLG adenomas.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404851.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 46
  •  go-up   go-down


50. Veras E, Mao TL, Ayhan A, Ueda S, Lai H, Hayran M, Shih IeM, Kurman RJ: Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol; 2009 Jun;33(6):844-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are frequently associated with endometriosis and, less often with clear cell adenofibromas.
  • We hypothesized that CCCs are a heterogeneous group of tumors, some arising from a cyst and others from an adenofibroma.
  • Various features were analyzed including: age, race, laterality, tumor size, architectural pattern (papillary, tubulo-cystic, solid, mixed patterns), grade, mitotic index, association with endometriosis including atypical endometriosis/intraepithelial carcinoma, stage and survival.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenofibroma / pathology. Cysts / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342944.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Soslow RA, Ali A, Oliva E: Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol; 2008 Jul;32(7):1013-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcomas (MAs) are rare mixed mesenchymal and epithelial neoplasms that occur most commonly in the uterus.
  • Although the epithelial component is typically benign, the mesenchymal component of most adenosarcomas morphologically resembles that observed in endometrial stromal tumors and is responsible for their clinical behavior.
  • Thus, the differential diagnosis usually includes not only low-grade endometrial stromal tumors, but also adenofibroma, carcinosarcoma, and embryonal rhabdomyosarcoma especially in small samples.
  • Expression of c-kit and inhibin in greater than 5% of the tumor cells was not encountered.
  • [MeSH-major] Adenosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / diagnosis. Biomarkers, Tumor / analysis. Cell Proliferation. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Rhabdomyosarcoma, Embryonal / diagnosis. Sarcoma, Endometrial Stromal / diagnosis. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469708.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


52. Carter A, Quddus MR, Sung CJ, Lawrence WD: Pathologic quiz case: a 54-year-old woman with bilateral pelvic masses. Well-differentiated papillary serous carcinoma arising in serous adenofibroma of borderline malignancy. Arch Pathol Lab Med; 2005 Jan;129(1):e25-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic quiz case: a 54-year-old woman with bilateral pelvic masses. Well-differentiated papillary serous carcinoma arising in serous adenofibroma of borderline malignancy.
  • [MeSH-major] Adenofibroma / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Pelvis / pathology. Uterine Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628924.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Subhawong TK, Subhawong AP, Hamper UM: Serous adenofibroma of the testicle: case report and review of the literature. J Ultrasound Med; 2010 Jan;29(1):135-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenofibroma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenofibroma of the testicle: case report and review of the literature.
  • [MeSH-major] Adenofibroma / surgery. Adenofibroma / ultrasonography. Orchiectomy. Testicular Neoplasms / surgery. Testicular Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040787.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down






Advertisement